

Supplementary Information for

## **Translational switching of Cry1 protein expression confers reversible control of circadian behaviour in arrhythmic Crydeficient mice**

Elizabeth S. Maywood\*, Thomas S. Elliott, Andrew P. Patton, Toke P. Krogager, Johanna E. Chesham, Russell J. Ernst, Václav Beránek, Marco Brancaccio, Jason W. Chin, Michael H. Hastings\* +

Elizabeth S. Maywood, MRC Laboratory of Molecular Biology, Neurobiology Division, Francis Crick Ave., Cambridge CB2 0QH. U.K. Tel: 0044 1223 267645. Email: emaywood@mrc-lmb.cam.ac.uk

Michael H. Hastings, MRC Laboratory of Molecular Biology, Neurobiology Division, Francis Crick Ave., Cambridge CB2 0QH. U.K. Tel: 00 44 1223 267045. Email: mha@mrc-lmb.cam.ac.uk

## **This PDF file includes:**

Figs. S1 to S8

## Supplementary Figure S1



**Figure S1. Control of cellular circadian rhythms by translational switching of Cry1 expression in organotypic Cry-null SCN slices.**

a) Expression of Cry1::EGFP relative to mCherry shows a dose-dependent increase, representing a dose-dependent increase in Cry1 expression. Mean±SEM ratio of EGFP to mCherry (n=4-6 SCN slices per dose) following addition of vehicle (0) or AlkK (0.3, 3mM) to the medium. In each slice the average, background subtracted ratio was taken from 40 cells over 2 fields of view (63x confocal image) (1xANOVA: F=16.95 df 2,12 p<0.001; post-hoc Tukey's multiple comparisons test \*p<0.05 0.3mM AlkK vs vehicle; 0.3mM vs 3mM AlkK; \*\*\*p<0.001 3mM AlkK vs vehicle). b) Representative traces from 4 SCN slices treated with 1mM AlkK showing the decrease in the level of Per2::Luc bioluminescence following expression of pCry1-Cry1( $_{177TAG}$ )::EGFP. Photomicrographs (x20; scale bar 100 $\mu$ m) show the colocalisation of Cry1::EGFP and mCherry (yellow/orange cells) at the peak but not at the trough of the Per2::Luc bioluminescence cycle c) Comparison between the mean (±SEM, dashed lines) decrease in bioluminescence recording from Cry1, 2-null Per2::Luc SCN slices (n=7) immediately following addition of 1mM AlkK ("initiation"; black line) and during the  $1<sup>st</sup> TTFL-driven oscillation ("1<sup>st</sup> peak", red line). Grey bars$ represent significant differences between the "initiation" and "1<sup>st</sup> peak"; dark grey  $p<0.001$ ; mid grey  $p<0.01$ ; light grey  $p<0.05$ .



Supplementary Figure 2



a) Representative pixel-based images of trough and peak bioluminescence, with corresponding standard deviation of signal over SCN during pre-AlkK baseline (left), during 1mM AlkK (centre) and following wash-out of AlkK (right) (images from Slice B). b) Corresponding FFT determined period, normalised amplitude, RAE (relative amplitude error) and GOF (goodness of fit) of cellular circadian oscillations from Slice B showing the coherence of the cellular rhythms during AlkK treatment but not during baseline or washout (mean±SD shown in magenta overlayed on top of the individual values).





**Figure S3. Control of circuit-level circadian organisation by translational switching of Cry1 expression in organotypic Cry-null SCN slices.**

Phase distribution maps and associated Rayleigh plots from 4 independent Cry1, 2-null SCN slices (A-D) transduced with the AAV pCry1- Cry1(177TAG)::EGFP. Data presented during the baseline (left), 1mM AlkK treatment (centre) and washout (right). Extreme right shows phase distribution during AlkK treatment but with an expanded scale (-3 to 3h vs - 20 to 20h).



**Figure S4. Control of cellular circadian rhythms by translational switching of Cry1 expression in organotypic Cry-null SCN slices is dependent on inter-cellular communication.**

a) Per2::Luc bioluminescence traces from Cry1, 2-null SCN slices transduced with AAV pCry1-Cry1(177TAG)::EGFP and treated with 1mM

AlkK (magenta) followed by either vehicle or b) 1mM TTX (n=3/group). c) As in a) for slices treated with vehicle then AlkK ( $n=3$ ), or d) TTX and then AlkK (n=4). e) Mean (±SEM, dashed lines) detrended bioluminescence traces from a) to d). The black dashed line aligns the  $1<sup>st</sup> TTFL-driven peak$ following treatment with 1mM AlkK.



Supplementary Figure S5

**Figure S5. Translational switching of Cry1::EGFP expression in the SCN controls circadian behaviour of Cry1, 2-null mice.**

a) Photomicrographs (20x magnification, 4x4 tiled) showing the rostrocaudal coronal distribution of  $Cry1<sub>(177TAG)</sub>:EGFP$  expression in the hypothalamus of 5 representative Cry1, 2-null mice (3V: 3<sup>rd</sup> ventricle; AC: anterior comminsure; OC: optic chiasm; POA: preoptic area; MBH: mediobasal hypothalamus) (Scale bar =  $500 \mu m$ ). b) Representative double-plotted actograms of wheel-running behaviour of the same mice as in (a) transferred to DD and provided with AlkK in drinking water. The traces are doubleplotted on a 24h time base.

Supplementary Figure S6



**Figure S6. Quality and coherence of circadian behaviour initiated in Cry1, 2-null mice by translational switching of Cry1::EGFP expression in the SCN.**

a, b) Representative double-plotted actograms of wheel-running behaviour of wild-type (a) or Cry2-null (b) mice. c- f) Group data (mean±SEM; n=6- 11) for c) circadian period, d) non-parametric relative amplitude, e) intradaily variability and f) inter-daily stability of circadian wheel-running behaviour of wild-type (black;  $n=11$ ) or Cry2-null mice (grey;  $n=8$ ); or Cry1, 2-null mice injected with control AAV pCry1-EGFP (green; n=6) or non-conditional pCry1-Cry1::EGFP (red; n=6); or Cry1, 2-null mice injected with  $AAV$  encoding aminoacyl-tRNA synthetase/  $tRNA<sub>CUA</sub>$  pair, plus  $pCry1-Cry1<sub>(177TAG)</sub>:EGFP and treated with vehicle (light blue; n=11) or$ AlkK (magenta; n=11) for translational switching. (Period: post hoc Tukey's multiple comparison test \*p<0.05 AlkK vs AAV pCry1-Cry1::EGFP; \*\*\*p<0.001 vs wild-type and Cry2-null;  $x^{x}$  p<0.005 wild-type vs Cry2-null. Relative amplitude:  $1xANOVA$ : F=3.2 df 3,32 p<0.05; post hoc Tukey's multiple comparison test \*p<0.05 AlkK vs wild-type. Intradaily variability: 1xANOVA:  $F=12.1$  df 3,32 p<0.0001; post hoc Tukey's multiple comparison test \*\*p<0.005 AlkK vs Cry2-null,  $xxx$  p<0.0001 WT vs Cry2null. Interdaily stability: 1xANOVA: F=22.4 df 3,32 p<0.0001; post hoc Tukey's multiple comparison test \*\*\*p<0.0001 AlkK vs wild-type;  $xxx$  p<0.0001 WT vs Cry2-null and AAV pCry1-Cry1::EGFP.).



Supplementary Figure S7

Time, weeks

**Figure S7. Effect of AlkK on drinking water consumption and maintenance of body weight.**

a) Weekly fluid intake of Cry1, 2-null mice treated sequentially with AlkK, vehicle and AlkK (blue; n=5), or vehicle, AlkK and vehicle (red; n=6) in drinking water. Shaded blue and red blocks indicate phase of AlkK treatment. \*\*\* p<0.001 between groups (2xANOVA: Interaction F=55.0, df 8,75, p<0.0001; Time F=17.7 df 8,75 p<0.0001; Treatment F=2.0 df 1,75 p<0.05; post hoc Sidak's multiple comparisons test \*\*\*\*p<0.0001, \*\*\*p<0.001). b) Weekly change in body weight (mean+SEM), potted as in (a).  $(2x \text{ RM ANOVA:}\$  Interaction F=13.8, df 9,81, p=0.09; Time F=12.1 df 9,81 p=0.16; Treatment F=0.3 df 1,9 p=0.99).

Supplementary Figure S8



**Figure S8. Comparison of circadian behavioural profiles of Cry1, 2-null mice undergoing translational switching of Cry1 expression and wildtype and Cry2-null mice**.

a) Single-plotted group circadian activity profiles (mean $\pm$ SEM, n =11/group) of AAV-injected Cry1, 2-null mice provided with vehicle (light blue) or AlkK (magenta) in their drinking water (Grey box denotes subjective night). b) Circadian activity profile as in (a) for AlkK-treated mice (magenta,  $n=11$ ), plotted alongside wild-type (black,  $n=11$ ) and Cry2-null (grey,  $n=8$ ) mice. (2xANOVA RM: Interaction F=12.5, df 90,1035, p<0.0001; Time F=32.4, df 45,1035, p<0.0001; Group F=4.5, df 2,23, p<0.005.